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ImmunoglobulinThe entire repertoire of antibodies in our serum, the IgOme, is a historical record of our past expe-
riences and a reﬂection of our immune status at any given moment. Understanding the dynamics of
the IgOme and how the diversity and speciﬁcities of serum antibodies change in response to disease
and maintenance of homeostasis can directly impact the ability to design and develop novel vac-
cines, diagnostics and therapeutics. Here we review both direct and indirect methodologies that
are being developed to map the complexity and speciﬁcities of the antibodies in polyclonal serum
– the IgOme.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Over a Century has passed since the ﬁrst Nobel Prize in Medi-
cine (1901) was awarded to Emil von Behring for ‘‘his work on ser-
um therapy . . . by which he opened a new road in the domain of
medical science and thereby placed in the hands of the physician
a victorious weapon against illness and death’’ [1]. Serum is indeed
a ‘‘victorious weapon’’ able to neutralize pathogens through the
exquisite speciﬁcity of its antibodies that seem endless in their
capacity to discriminate and bind the vast structural complexities
found in nature. Susumu Tonegawa’s Nobel Prize (1987) recog-
nized the elucidation of the genetic principles for the generation
of this antibody diversity [2]. Application of these principles allows
the derivation of the total ‘‘potential repertoire’’ of antibodies in
humans; the combinatorial multiplication of all the V, D, and J seg-
ments of the Heavy (H) chains times the combined product of the V
and J segments of the kappa and lambda Light (L) chains as well as
the contributions of the N and P nucleotides associated with the
junctional complexity – leading to an extraordinary vast theoreti-
cal number, 1011–1012, that far exceeds the total number of B-cells
in a person’s body [34,65]. More realistic is the ‘‘available reper-toire’’ of variant B-cells that has been calculated to be in the order
of 107 per person [9]. Howmany of these B-cells subtypes are actu-
ally utilized for the production of distinct antibodies probably does
not exceed more than tens of thousands in a person’s life time. Sur-
prisingly, whereas pathogens come and go as they are cleared from
our bodies, the antibodies generated in response to immunological
insults are archived in our memory B-cells, the cells that orches-
trate the continuous production of antibodies found in serum over
the course of our lives. This entire utilized repertoire of antibodies
in our serum, the IgOme, is a historical record of our past experi-
ences and a reﬂection of our immune status at any given moment.
Understanding the IgOme, how homeostasis is maintained, how
‘‘serum memory’’ is affected by immunization, boosts, encounters
with pathogens, physiology and old age are all fundamental ques-
tions of great interest. The answers to these questions bear directly
on the development of novel vaccines, diagnostics and therapeu-
tics and in order to meet these challenges one must be able to pro-
ﬁle the IgOme. We need to be able to describe the IgOme in its
entirety at single antibody resolution in a manner that is cost effec-
tive and expedient. One could then imagine running IgOme screens
routinely in the course of personalized medical diagnosis and
treatment. Obviously, the challenge is formidable – just consider-
ing the diversity of antibodies and the dynamics of their expression
at any given moment and as a result to any given stimulus. Here
we review a variety of technical approaches designed to proﬁle ser-
um antibody diversity in the quest of describing the complexity
and composition of the human IgOme.
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Two basically different approaches have been employed in the
analysis of the antibody repertoire of serum. The ‘‘Direct’’ approach
goes to proﬁle the antibodies or antibody-producing cells them-
selves. For this, one can catalogue antibodies based on proteomic
sequencing or achieve the same by genomic sequencing of anti-
body transcripts derived from peripheral B-cells. The ultimate goal
would be to rank the antibodies by relative concentration and cat-
egorize them by antigen speciﬁcity. The ‘‘Indirect’’ approach uses
surrogate measures to extrapolate antibody species based on pro-
teins or peptides they bind. Hence, the IgOme proﬁle would be a
list of inferred antibody speciﬁcities. First we address the ‘‘Direct’’
analysis of the IgOme.3. Direct IgOme proﬁling
3.1. Phage display of antibodies
Conceptually, proﬁling the IgOme in its entirety would be com-
plete were one able to systematically clone the antibodies in poly-
clonal serum, one by one and catalogue them by frequency of
usage along with their corresponding antigen speciﬁcities. Clearly,
classical methods for the production of monoclonal Antibodies
(mAbs) are not suitable for such massive comprehensive screening,
not in mice and deﬁnitely not for humans (see for example reviews
[40,58,97]).
The introduction of phage display libraries of antibodies, how-
ever, provided a breakthrough in that one could, in theory, pre-
serve the entire repertoire of the Heavy (H) and Light (L) chains
of a person to be later screened for various antigen speciﬁcities
[16,43a,60]. Two types of antibody phage display libraries can be
constructed: ‘‘naïve’’ and ‘‘immunized’’ libraries. Both types of li-
braries are generated to discover details of the immune response
to a given pathogen, autoimmune disease or cancer
[5,20,21,26,46,56,86,102]. Naïve libraries generated from random
donors are presumed to represent the ‘‘healthy’’ human repertoire
of antibodies in general. In principle, naïve libraries offer the pos-
sibility of selection of high afﬁnity antibodies of any desired spec-
iﬁcity without the need for selectively stimulating the immune
response with a speciﬁc antigen. Using naïve libraries, there has
been considerable success for isolating mAbs against various
pathogens, such as SARS-CoV [69,86], WNV [37], and HBV [49].
The second class of library, the ‘‘immunized phage-displayed anti-
body library’’ is constructed from the mRNA from a donor who was
exposed to infection/vaccination with a deﬁned antigen, therefore
his immune response has been speciﬁcally stimulated. For immu-
nized libraries, it is generally preferable to use a donor with a high
serum antibody titer for the antigen/pathogen of interest. A high
serum titer is presumed to reﬂect relatively high levels of Ab pro-
duction and therefore higher levels of speciﬁc mRNA should be
obtainable for the generation of the library [17]. This approach
has been successful for isolating mAbs speciﬁc for diverse patho-
gens, such as, H5N1 [46,90], foot and mouth disease [31] and
HIV [6,23,41,64,101,102].
In the matter of HIV-1, isolation of potent neutralizing mAbs
has only been successful using immunized libraries (as compared
to naïve libraries). These have been constructed from selected do-
nors that have proven neutralizing activity. A case in point is the
study by Burton and Barbas where an antibody library was pro-
duced from a 31-year old, HIV-1 positive, homosexual male, who
had been asymptomatic for six years [5,16]. A Fab library was con-
structed on the surface of ﬁlamentous phage which comprised 107
members. This library was then screened against monomeric
glycosylated HIV-1 gp120IIIB from which a collection of 20 phagedisplayed mAbs was isolated. The most potent was mAb b12,
which competes for the binding site of HIV-1 gp120 receptor
(CD4) and thus prevents virus binding to its target cell. Co-crystal-
lization of this mAb with core gp120 conﬁrmed the epitope overlap
with the CD4 binding site [105]. Moreover, these b12 studies were
revealing of two major drawbacks of the phage display technology:
(i) This methodology is still relatively time consuming, tedious, and
somewhat inefﬁcient. Typically in standard experiments only tens
of mAbs are isolated which are speciﬁc towards the antigen against
which they were screened. (ii) The natural pairing of immunoglob-
ulin H and L chains is lost in the construction of the library, thus
the vast majority of the antibodies produced are the result of ran-
dom, arbitrary pairing which does not reﬂect the natural H:L pair
of the B-cell clone that produced them. Indeed, the co-crystalliza-
tion of mAb b12 shows that the L chain does not contribute to
gp120 recognition at all. All the contacts are made exclusively via
the H chain [105]. Thus, indicating that the L chain used is most
probably not the H chain’s natural partner. Generally, it has been
estimated that when constructing an Ab phage display library from
total H and L chain cDNAs derived from Peripheral Blood Mononu-
clear Cells (PBMCs) and generating a complexity of 108 phage dis-
played antibodies, only 10000 mAbs are expected to maintain their
native H:L pair [40].
Another drawback of the phage display antibody system is that
some VH:VL pairs may be toxic and impair bacterial growth. This in
turn may lead to a very biased representation of antibodies when
phage display is used for antibody expression [75].
Nonetheless, the power of phage-displayed antibody libraries is
the ability to immortalize the entirety of the available naïve poten-
tial of H and L chains and even expand upon it by generating novel
pairs that do not naturally exist in the donor’s repertoire.
3.2. Next Generation Sequencing of antibody H and L chain mRNAs
The premise for these analyses is that one can apply Next Gen-
eration Sequencing (NGS) to catalogue the entire complexity of
antibody related transcripts of a given individual [13,34,96]. For
this, high throughput sequencing is typically performed using the
454 pyrosequencing analyses that currently generate >106 se-
quences of 400–500 bp long. Thus, one can read beyond the three
CDRs of a chain in a single run [3,8,13,34,96,100,106].
When total PBMCs are used, such analyses typically address the
available repertoire and not necessarily the utilized repertoire.
Thus for example, Glanville et al. conducted their analyses on
pooled phage displayed IgM antibodies derived from 654 healthy
human donors [34]. This study serves as a comprehensive and de-
tailed analysis of the ‘‘available IgOme’’ and produces a baseline of
sorts for the ‘‘average’’ human repertoire. The total diversity of the
combinatorial Ab library was calculated to be 3.5  1010. This li-
brary, when screened using 16 different antigens, produced a col-
lection of antigen speciﬁc antibodies that when analyzed using
NGS, were found to comprise all the human germline VDJ and VJ
segments as expected. Moreover, this analysis provides insights
to the relative frequency of the usage of V segments.
Application of NGS to the study of antibodies has increased our
understanding of the general physical traits of antibodies produced
in humans, such as: prevalence of usage of various germline V, D
and J segments, for a given class of antigen [100]. Another subject
of interest has been the speciﬁc focus on the characterization of
HCDR3 loops, regarding their amino acid lengths and the number
of ‘‘in-dels’’ detected in the generation of extended CDR3 loops
[3,14,20,34,100]. Moreover, it emphasizes the power of NGS tech-
nology that provides a quality assurance to identify and correct
biases that may be introduced during the procedure of library con-
struction such as over representation or the absence of a speciﬁc
segment [34].
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notypes of B-cells which have been deﬁned as those transcripts
that have identical germline V and J segment usage, identical
CDR3 amino acid length and at least 80% amino acid homology
[62,68,98]. The clonotypes can then be ranked based on their fre-
quency in any given serum sample. Moreover, it has been sug-
gested that by ranking the frequency of H clonotypes vs. L
clonotypes, one can infer natural H:L pairs [70].
For analysis of the ‘‘utilized repertoire’’ one must resort to other
methods, such as sorting memory B-cells as the source of the
mRNA transcripts, or comparing transcripts corresponding to IgM
vs. IgG [11,51–53,67]. An example is the study of Wu et al. [100]
in which NGS analyses of two HIV infected individuals (ca.
>220000 sequences for each) were utilized to identify VH se-
quences which resemble the sequence of the highly potent neutral-
izing mAb VRC01 [99]. By comparing the sequences obtained from
both patients to the VRC01 sequence, they could follow the afﬁnity
maturation pathway leading to this unique class of antibodies.
Similar studies using NGS and addressing the maturation of HIV
speciﬁc mAbs have been reported by others [14,20,100,106].
Although such NGS analyses of total RNA do not allow natural
pairing of the VH and VL chains or determine antibody speciﬁcity,
they do teach general structural characteristics of the antibody
repertoire in a given person and the response in a given clinical sta-
tus. Thus for example, sera of people infected by speciﬁc pathogens
or suffering from cancer or autoimmunity disease, can be com-
pared to control-sera which might lead to the identiﬁcation of spe-
ciﬁc markers which can be used, for example, in diagnostic
applications [13,25,57,100].
3.3. Single cell cloning
Since 2009, several new and improved techniques for isolation
of human mAbs have emerged. Within a very limited period, there
has been a burst of innovation that has driven the ﬁeld from the
isolation of a limited few to the production of hundreds of mAbs
[38,77,79,94,99]. These all start from sorting of antigen-speciﬁc
memory B-cells, the ability to perform single cell PCR transcript
ampliﬁcation, and eventual effective cloning and expression of Ig
H and Ig L genes derived from individual B-cells. The success of
these novel technologies is based primarily on two major develop-
ments and improvements:
(i) The source of mRNA – using single cell memory B-cells as the
source of RNA. Of particular signiﬁcance is the work of
Lanzavecchia and co-workers who discovered that memory
B-cells proliferate and secrete antibody in response to CpG
oligonucleotides, without the need of antigenic stimulation
[52,91]. Furthermore, memory B-cells can be efﬁciently
sorted based on the surface markers they display such
as: IgG+ or IgA+, CD19+, CD27+ and lack of ABCB1
[11,51–53,67]. This has paved the way to what has proven
to be the most effective method for selecting antigen speciﬁc
mAbs from a given individual [12,38,61,77,94,99]. A case in
point is the study of Walker et al. [94] who ﬁrst screened
1800 HIV infected individuals for potent serum cross neu-
tralizing activity so to identify a particularly effective donor
of memory B cells (a clade A-infected African patient, as
opposed to Glanville et al. [34] who used 654 donors pooled
all together). They then used a high-throughput neutraliza-
tion screen of antibody-containing culture supernatants
from approximately 30000 activated memory B cells from
the donor. This led to the isolation of two novel broadly cross
neutralizing mAbs, PG9 and PG16.(ii) Improved design of primers – Broadly cross neutralizing mAbs
against HIV have been discovered to contain exceptionally
high levels of point mutations acquired during the course of
somatic hypermutation and afﬁnity maturation [106]. As a
result, this hypervariability can interfere with the isolation
ofmAb transcripts. In order to overcome this problem, Scheid
et al. redesigned the set of primers so that the 50 primer is set
further upstream to avoid the hyper-mutated regions [79].
Applying this approach led to the successful cloning, isolation
and characterization of 576 new antibodies of HIV envelope bind-
ing memory B cells, from four HIV infected individuals. Hence, a
remarkable improvement in the efﬁciency of mAb isolation was
realized [79]. Obviously, by dramatically increasing the number
of antibodies isolated with a distinct afﬁnity along with their
sequencing, one can identify generalities and how the immune sys-
tem responds and is able to neutralize a given virus.
Since the study of Walker et al., a number of groups have re-
ported variations conforming to a general paradigm where one
screens the afﬁnity selected memory B-cells followed by single cell
cloning of their cognate H and L chains that then guide the con-
struction of their functional antibodies via recombinant DNA tech-
nologies [38,61,77,99].
Whereas many of the analyses discussed thus far have dealt
with the genetic bases for Ab production and expression they do
not necessarily address the actual physical nature of antibodies ex-
pressed in the serum. Hence, combining proteomics with NGS has
been the next step.
3.4. Combining proteomics with NGS
Despite the elegance of single cell cloning of natural mAbs from
memory B-cells, these efforts go to produce select antigen speciﬁc
mAbs rather than provide insights to the general diversity of anti-
bodies physically present and ‘‘used’’ in the serum.
To address the challenge of deconvoluting the diversity of Abs
present in polyclonal serum, two groups have successfully proven
feasibility in combining proteomics with NGS techniques for the
analysis of the serum antibodies response, although still to speciﬁc
antigens [22,98]. Cheung et al. conducted a study to investigate the
mAb composition of polyclonal serum of rabbits immunized with
progesterone A/B (PR A/B) peptides [22]. While Wine et al. aimed
to deconvolute the polyclonal serum of a rabbit immunized with
Concholepas concholepas hemocyanin (CCH) as opposed to an unim-
munized rabbit [98]. In both cases the following general scheme
was used:
 Serum immunoglobulins are puriﬁed over protein A columns
and then subjected to antigen afﬁnity chromatography to iso-
late antigen speciﬁc IgGs.
 The puriﬁed Ab fraction is analyzed by liquid chromatography
coupled to tandem mass spectrometry (LC–MS/MS).
 Parallel to this effort, high-throughput DNA sequencing of the
immunized animal’s memory B-cells of both the H and the L
chains is performed to create a comprehensive data base of all
immunoglobulins that have been expressed and archived.
By comparing these two data sets one can draw a number of con-
clusions: (i) One can ascribe the CDR3s deﬁned by proteomic analy-
sis to full length VH chains derived from the NGS data, (ii) Once the
full length VH sequences have been identiﬁed, these can be ranked
based on their frequencies of the CDR3smapped by proteomic anal-
ysis, and (iii) Using different strategies, one can reconstitute anti-
bodies based on the most frequent VH chains identiﬁed.
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the antibodies represented by the IgOme in serum. They have
accomplished this by combining both proteomic and NGS data sets
thus illustrating that this general approach is feasible. Whereas
these studies are extremely important, the technology has yet to
be further developed in order to allow the transition from antigen
based IgOme analysis to the general comprehensive analyses of the
total IgOme in a given person.
4. Indirect IgOme proﬁling
Most certainly the production and analyses of antibodies has
come a long way since Köhler and Milstein introduced their mur-
ine hybridoma technology [50], the recent isolation of target-spe-
ciﬁc human mAbs derived from single memory B-cell clones [78]
and the ultimate comprehensive proteomic/NGS screens described
by Cheung and Wine [22,98]. However, all these efforts are still
very much single antigen oriented and do not provide a broader
appreciation of the diversity of antibody speciﬁcities actually
found in serum. For this, combinatorial peptide and protein arrays
have been proposed and perfected. Here we will focus on the use of
phage display peptide libraries. For reviews dealing with synthetic
peptide arrays and antigen arrays the reader is referred to speciﬁc
reviews [33,72].
4.1. Random phage display libraries
George Smith pioneered the concept of using random peptides
displayed on ﬁlamentous bacteriophages to interrogate antibodies
[84]. The initial application of such studies was to map a mAb’s
speciﬁc epitope via the peptides it was able to afﬁnity select from
a vast collection of random short peptides (6–15 amino acids long)
[15,32,81,84]. This exercise ﬁrst taught us the striking realization
that despite our notion of exquisite speciﬁcity of mAbs, in reality
it turns out that any given mAb most often can bind a rather larger
diversity of peptides that often show no obvious homology with
the linear amino acid sequence of that mAb’s cognate antigen
[15,89]. This is due to the fact that antibodies bind protein surfaces
that are comprised of discontinuous residues brought together
through protein folding [73]. Hence the typical epitope is both con-
formational and discontinuous. Thus, more than often the peptides
ﬁshed out of a random peptide library through speciﬁc binding are
peptido-mimetics that in some fashion represent complex surfaces
of the antigen recognized by the mAb.
Onemust consider, however, that antibodies do not always bind
protein epitopes. Thus, for example probes for phosphotyrosine [35]
as opposed to phosphoserine or phospothreonine [36,71] can be
developed illustrating that some antibodies can target the modiﬁed
amino acid. Moreover, antibodies are often speciﬁc for glycomoi-
eties as is the case for the immune response to the ABO blood types
[93]. Phagedisplay peptide libraries, expressed in bacteria obviously
cannot account for these post translationalmodiﬁcations of protein.
Nonetheless, phage display peptide analyses of sugar speciﬁc anti-
bodies have proven feasible as often the afﬁnity puriﬁed peptide is
a mimetic of a non-amino acid structure [7,82,88].
However, random peptide analyses generate collections of
afﬁnity puriﬁed peptides that represent a given mAb’s epitope
[15,89]. Thus, a number of computational methods have been
developed in which the peptides that have been afﬁnity selected
by a given mAb can be used as a database to predict its correspond-
ing epitope, provided an atomic structure of the antigen is avail-
able [15,18,27,32,39,59,63,80,89]. A case in point is the
application of the predictive algorithm Mapitope which has been
applied for the prediction of components of the epitope for the
HIV neutralizing mAb b12 (mentioned above) and for theSARS-CoV neutralizing epitope, 80R [15, 89]. These predictions
have then subsequently been conﬁrmed by X-ray analyses of anti-
body-antigen co-crystals [105, 43b].
Folorgi et al. were the ﬁrst to demonstrate the use of phage dis-
play libraries for the analysis of disease associated polyclonal ser-
um [30]. These investigators screened a library of random
nonapeptides using human sera taken from individuals vaccinated
with hepatitis B virus surface antigen (HBsAg) and compared these
to sera taken from healthy donors. They illustrated that panels of
peptides could be produced and corresponded with the viral
antigen.
Since these studies, the dissection and interrogation of the hu-
moral response seen in the polyclonal serum by random phage dis-
play has become a tool for epitope mapping, diagnostics and
prognostics of various clinical states, as detailed in Table 1.
As has been previously discussed for the use of phage display
antibodies, here too the screening process itself can be a long
and tedious process which results in the selection of only tens to
hundreds of afﬁnity selected peptides after weeks of screening.
Moreover, as any given mAb can select a diversity of tens of pep-
tides on its own, the generation of panels of even hundreds of pep-
tides by serum cannot faithfully represent the complexity of its
polyclonal composition.
4.2. Deep-Panning
In order to address these issues Deep-Panning has been pro-
posed; a method in which the power of NGS is combined with
the ﬂexibility of random peptide phage display for the analysis of
polyclonal serum [74]. Conceptually polyclonal serum is used to
screen a phage displayed random peptide library followed by
NGS of all the afﬁnity captured phages. The output of such an anal-
ysis is a vast collection of thousands to millions of peptide se-
quences that have been afﬁnity puriﬁed by the antibodies in a
given serum sample. The frequency a speciﬁc peptide is isolated,
indicates the titer and afﬁnity of its corresponding antibody. In
Deep-Panning there is no isolation or cloning of single phages,
rather the entire complexity of all phages harvested in a panning
experiment are directly sequenced, all at once. Moreover, deep-
sequencing allows parallel sequencing of tens of samples; each
sample is discriminated by a short DNA barcode (5 bases) intro-
duced during the PCR sample preparation.
An example of the use of Deep-Panning has been in the analysis
of HIV-1 infected polyclonal serum. A phage display library of 7
mer peptides was used to biopan a sample of puriﬁed human IgG
obtained from HIV-1 infected individuals (HIVIG). After three
rounds of biopanning against the HIVIG, the eluted phages were
used as templates for PCR ampliﬁcation. The PCR products were
deep-sequenced using the Illumina system [10]. A total of
163,400 peptides were obtained of which 7799 were unique se-
quences. Of these, peptides could be demonstrated that correspond
to HIV envelope showing that Deep-Panning of disease related ser-
um can generate a clear diagnostic signal indicating speciﬁc epi-
topes associated with the pathogen.
Thus, Deep-Panning illustrates the compatibility of combinato-
rial phage displayed libraries with NGS [74]. Comprehensive panels
of hundreds of thousands of afﬁnity selected phage display pep-
tides are produced and their frequencies and motif relevance en-
able one to categorize the speciﬁcities of a given polyclonal
serum. Further development of computational algorithms able to
handle the massive data generated from random peptide libraries
and catalogue the peptides into motifs could lead to the ability
to associate these with deﬁned epitopes and antigens. Thus,
Deep-Panning should become a practical tool for the proﬁling of
the IgOme.
Table 1
The usage of random peptide library for the analysis of polyclonal serum.
Disease Aim References
HIV Selection of speciﬁc mimotopes by plasma samples which deﬁned Long Term Non Progressors (LTNPs) HIV infected individuals as opposed to
progressor HIV infected patients
[42]
HIV Analysis of polyclonal serum from HIV-1 infected individuals corresponding to the pentameric loop of gp41 [28]
HIV Identiﬁcation of antigenic and immunogenic mimotopes of HIV-1 epitopes [76]
SIV Differentiation of a passive vaccine and the humoral immune response towards infection [83]
SIV Identiﬁcation of epitopes associated with vaccine protection in rhesus macaques [4]
SARS Discovery of disease-speciﬁc B cell epitopes for SARS-CoV [55]
HCV Discovery of disease-speciﬁc epitopes for HCV infected patients [87]
AS Selection of speciﬁc serum biomarker for ankylosing spondylitis (AS) [95]
MS Characterization of the antigenic epitopes speciﬁcally targeted by the sera of patients with multiple sclerosis (MS) [44]
Cancer Discovery of potential serum biomarkers for early primary Hepatocellular carcinoma (HCC) [103]
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In contrast to random peptide display, gene-fragment phage
display libraries offer an alternative that can simplify analyses
especially when one focuses on a speciﬁc antigen(s). The gene-
fragment phage display library can represent a gene [29], a cDNA
[19,24,29,45,85,104] or even a total genome [47,54] that encodes
the ligand of interest. The DNA is reduced to smaller gene frag-
ments (50–400 bp), usually by DNaseI-mediated random digestion
or by gene fragment synthesis [47,66,92]. These are cloned into the
50 terminus of the coat protein gene of the phage. The gene-frag-
ment phage display library is then used for biopanning against
polyclonal serum or speciﬁc mAbs, and has resulted in the isolation
of peptides which enable one to determine the corresponding epi-
topes of the Abs tested. These selected peptides can also be utilized
as biomarkers for various applications. Novel biomarkers, such as
circulating (auto) antibody signatures, may improve diagnosis,
prognosis and treatment of cancer [19,104], autoimmune [54,85]
and infectious-diseases [48]. For example, Chatterjee et al. utilized
a cDNA phage display library to identify diagnostic markers for
ovarian cancer [19]. Their 65 selected clones interacted with sera
from 32 ovarian cancer patients but not with sera from 25 healthy
women or 14 patients suffering from other benign or malignant
gynecologic diseases. Thus, the panel of biomarkers was found efﬁ-
cient for detection of ovarian cancer. However, this platform has
limitations as well. The abundance of fragments that are cloned
are often out of reading frame, consequently the identiﬁcation of
the epitopes is not straightforward. For example, only 12 out of
the 65 clones, selected by Chatterjee et al., could clearly be shown
to correspond to linear segments of known antigens. The remain-
ing clones were either unidentiﬁed or had weak homology with
known proteins and thus were assumed to represent mimetics of
more complicated conformational epitopes.
Although these libraries are of limited diversity (as opposed to
random peptide libraries), this approach has been proven as inex-
pensive and high-throughput. Moreover, this method allows for di-
rect mapping of the epitope on the antigen sequence, as opposed to
phage display random peptide libraries in which epitope mapping
is not straight forward.
A tour de force demonstration regarding gene fragments is the
study of Larman et al. [54] who emphasized the strength of com-
bining deep-sequencing with phage display. These investigators
constructed a complete human proteome in the form of tiled over-
lapping peptides. For the synthetic representation of the proteome,
they generated phage display libraries which were made from
413611 DNA sequences encoding 36 amino acid peptides that span
24239 unique open reading frames. The DNA oligonucleotides
were robotically synthesized and cloned using the T7 phage dis-
play system. The ﬁnal library obtained, was screened against spinal
ﬂuids of patients suffering from neurologic autoimmune disease.
These screens resulted in the identiﬁcation of 16 autoantigencandidates of which four are considered potential diagnostic mark-
ers. The authors propose that further improvement of their meth-
odology may be realized by construction of peptides of greater
lengths which could extend the analyses to more conformational
epitopes.
5. Summary
Direct and Indirect methods are being used to proﬁle the com-
plexity and composition of antibodies in polyclonal serum. For the
present, most of these technologies have proven efﬁcient when ap-
plied to the humoral response towards speciﬁc antigens or patho-
gens. Nonetheless, the examples discussed serve as practical
illustrations of how we should be able to cope with the vast diver-
sity of antibodies that comprise the IgOme. Much progress has
been made both in antibody isolation and molecular characteriza-
tion of the antigens/peptides they bind. Further reﬁnement of the
methods described should lead, in the not too distant future, to a
comprehensive portrayal of the human IgOme.
References
[1] 1901. The Nobel Prize in Physiology or Medicine 1901.
[2] 1987. The Nobel Prize in Physiology or Medicine 1987.
[3] Arnaout, R., Lee, W., Cahill, P., Honan, T., Sparrow, T., Weiand, M., Nusbaum,
C., Rajewsky, K. and Koralov, S.B. (2011) High-resolution description of
antibody heavy-chain repertoires in humans. PLoS One 6, e22365.
[4] Bachler, B.C., Humbert, M., Palikuqi, B., Siddappa, N.B., Lakhashe, S.K.,
Rasmussen, R.A. and Ruprecht, R.M. (2013) Novel biopanning strategy to
identify epitopes associated with vaccine protection. J. Virol. 87, 4403–4416.
[5] Barbas 3rd, C.F., Bjorling, E., Chiodi, F., Dunlop, N., Cababa, D., Jones, T.M.,
Zebedee, S.L., Persson, M.A., Nara, P.L., Norrby, E., et al. (1992) Recombinant
human Fab fragments neutralize human type 1 immunodeﬁciency virus
in vitro. Proc. Natl. Acad. Sci. USA 89, 9339–9343.
[6] Barbas 3rd, C.F., Collet, T.A., Amberg, W., Roben, P., Binley, J.M., Hoekstra, D.,
Cababa, D., Jones, T.M., Williamson, R.A., Pilkington, G.R., et al. (1993)
Molecular proﬁle of an antibody response to HIV-1 as probed by
combinatorial libraries. J. Mol. Biol. 230, 812–823.
[7] Barenholz, A., Hovav, A.H., Fishman, Y., Rahav, G., Gershoni, J.M. and
Bercovier, H. (2007) A peptide mimetic of the mycobacterial mannosylated
lipoarabinomannan: characterization and potential applications. J. Med.
Microbiol. 56, 579–586.
[8] Bashford-Rogers, R.J., Palser, A.L., Huntly, B.J., Rance, R., Vassiliou, G.S.,
Follows, G.A. and Kellam, P. (2013) Network properties derived from deep
sequencing of human B-cell receptor repertoires delineate B-cell populations.
Genome Res. 23, 1874–1884.
[9] Benichou, J., Ben-Hamo, R., Louzoun, Y. and Efroni, S. (2011) Rep-Seq:
uncovering the immunological repertoire through next-generation
sequencing. Immunology 135, 183–191.
[10] Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., Smith, G.P., Milton, J.,
Brown, C.G., Hall, K.P., Evers, D.J., Barnes, C.L., Bignell, H.R., Boutell, J.M.,
Bryant, J., Carter, R.J., Keira Cheetham, R., Cox, A.J., Ellis, D.J., Flatbush, M.R.,
Gormley, N.A., Humphray, S.J., Irving, L.J., Karbelashvili, M.S., Kirk, S.M., Li, H.,
Liu, X., Maisinger, K.S., Murray, L.J., Obradovic, B., Ost, T., Parkinson, M.L.,
Pratt, M.R., Rasolonjatovo, I.M., Reed, M.T., Rigatti, R., Rodighiero, C., Ross,
M.T., Sabot, A., Sankar, S.V., Scally, A., Schroth, G.P., Smith, M.E., Smith, V.P.,
Spiridou, A., Torrance, P.E., Tzonev, S.S., Vermaas, E.H., Walter, K., Wu, X.,
Zhang, L., Alam, M.D., Anastasi, C., Aniebo, I.C., Bailey, D.M., Bancarz, I.R.,
Banerjee, S., Barbour, S.G., Baybayan, P.A., Benoit, V.A., Benson, K.F., Bevis, C.,
Black, P.J., Boodhun, A., Brennan, J.S., Bridgham, J.A., Brown, R.C., Brown, A.A.,
Y. Weiss-Ottolenghi, J.M. Gershoni / FEBS Letters 588 (2014) 318–325 323Buermann, S., Bundu, A.A., Burrows, J.C., Carter, N.P., Castillo, N., Chiara,
E.C.M., Chang, S., Neil Cooley, R., Crake, N.R., Dada, O.O., Diakoumakos, K.D.,
Dominguez-Fernandez, B., Earnshaw, D.J., Egbujor, U.C., Elmore, D.W., Etchin,
S.S., Ewan, M.R., Fedurco, M., Fraser, L.J., Fuentes Fajardo, K.V., Scott Furey, W.,
George, D., Gietzen, K.J., Goddard, C.P., Golda, G.S., Granieri, P.A., Green, D.E.,
Gustafson, D.L., Hansen, N.F., Harnish, K., Haudenschild, C.D., Heyer, N.I.,
Hims, M.M., Ho, J.T., Horgan, A.M., et al. (2008) Accurate whole human
genome sequencing using reversible terminator chemistry. Nature 456, 53–
59.
[11] Bernasconi, N.L., Traggiai, E. and Lanzavecchia, A. (2002) Maintenance of
serological memory by polyclonal activation of human memory B cells.
Science 298, 2199–2202.
[12] Bonsignori, M., Moody, M.A., Parks, R.J., Holl, T.M., Kelsoe, G., Hicks, C.B.,
Vandergrift, N., Tomaras, G.D. and Haynes, B.F. (2009) HIV-1 envelope
induces memory B cell responses that correlate with plasma antibody levels
after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183,
2708–2717.
[13] Boyd, S.D., Marshall, E.L., Merker, J.D., Maniar, J.M., Zhang, L.N., Sahaf, B.,
Jones, C.D., Simen, B.B., Hanczaruk, B., Nguyen, K.D., Nadeau, K.C., Egholm, M.,
Miklos, D.B., Zehnder, J.L. and Fire, A.Z. (2009) Measurement and clinical
monitoring of human lymphocyte clonality by massively parallel VDJ
pyrosequencing. Sci. Transl. Med. 1, 12ra23.
[14] Briney, B.S., Willis, J.R. and Crowe Jr., J.E. (2012) Human peripheral blood
antibodies with long HCDR3s are established primarily at original
recombination using a limited subset of germline genes. PLoS One 7, e36750.
[15] Bublil, E.M., Yeger-Azuz, S. and Gershoni, J.M. (2006) Computational
prediction of the cross-reactive neutralizing epitope corresponding to the
[corrected] monclonal [corrected] antibody b12 speciﬁc for HIV-1 gp120.
FASEB J. 20, 1762–1774.
[16] Burton, D.R., Barbas 3rd, C.F., Persson, M.A., Koenig, S., Chanock, R.M. and
Lerner, R.A. (1991) A large array of human monoclonal antibodies to type 1
human immunodeﬁciency virus from combinatorial libraries of
asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88,
10134–10137.
[17] Barabas III, C.F., Burton, D.R., Scott, J.K. and Silverman, G.J. (2001) Phage
Display A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, New York.
[18] Castrignano, T., De Meo, P.D., Carrabino, D., Orsini, M., Floris, M. and
Tramontano, A. (2007) The MEPS server for identifying protein
conformational epitopes. BMC Bioinformatics 8 (Suppl 1), S6.
[19] Chatterjee, M., Mohapatra, S., Ionan, A., Bawa, G., Ali-Fehmi, R., Wang, X.,
Nowak, J., Ye, B., Nahhas, F.A., Lu, K., Witkin, S.S., Fishman, D., Munkarah, A.,
Morris, R., Levin, N.K., Shirley, N.N., Tromp, G., Abrams, J., Draghici, S. and
Tainsky, M.A. (2006) Diagnostic markers of ovarian cancer by high-
throughput antigen cloning and detection on arrays. Cancer Res. 66, 1181–
1190.
[20] Chen, W., Prabakaran, P., Zhu, Z., Feng, Y., Streaker, E.D. and Dimitrov, D.S.
(2012) Characterization of human IgG repertoires in an acute HIV-1 infection.
Exp. Mol. Pathol. 93, 399–407.
[21] Chen, W., Streaker, E.D., Russ, D.E., Feng, Y., Prabakaran, P. and Dimitrov, D.S.
(2012) Characterization of germline antibody libraries from human umbilical
cord blood and selection of monoclonal antibodies to viral envelope
glycoproteins: implications for mechanisms of immune evasion and design
of vaccine immunogens. Biochem. Biophys. Res. Commun. 417, 1164–1169.
[22] Cheung, W.C., Beausoleil, S.A., Zhang, X., Sato, S., Schieferl, S.M., Wieler, J.S.,
Beaudet, J.G., Ramenani, R.K., Popova, L., Comb, M.J., Rush, J. and Polakiewicz,
R.D. (2012) A proteomics approach for the identiﬁcation and cloning of
monoclonal antibodies from serum. Nat. Biotechnol. 30, 447–452.
[23] Choudhry, V., Zhang, M.Y., Sidorov, I.A., Louis, J.M., Harris, I., Dimitrov, A.S.,
Bouma, P., Cham, F., Choudhary, A., Rybak, S.M., Fouts, T., Monteﬁori, D.C.,
Broder, C.C., Quinnan Jr., G.V. and Dimitrov, D.S. (2007) Cross-reactive HIV-1
neutralizing monoclonal antibodies selected by screening of an immune
human phage library against an envelope glycoprotein (gp140) isolated from
a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363, 79–
90.
[24] Cleutjens, K.B., Faber, B.C., Rousch, M., van Doorn, R., Hackeng, T.M., Vink, C.,
Geusens, P., ten Cate, H., Waltenberger, J., Tchaikovski, V., Lobbes, M., Somers,
V., Sijbers, A., Black, D., Kitslaar, P.J. and Daemen, M.J. (2008) Noninvasive
diagnosis of ruptured peripheral atherosclerotic lesions and myocardial
infarction by antibody proﬁling. J. Clin. Invest. 118, 2979–2985.
[25] Dunn-Walters, D.K. and Ademokun, A.A. (2010) B cell repertoire and ageing.
Curr. Opin. Immunol. 22, 514–520.
[26] Edwards, B.M., Barash, S.C., Main, S.H., Choi, G.H., Minter, R., Ullrich, S.,
Williams, E., Du Fou, L., Wilton, J., Albert, V.R., Ruben, S.M. and Vaughan, T.J.
(2003) The remarkable ﬂexibility of the human antibody repertoire; isolation
of over one thousand different antibodies to a single protein, BLyS. J. Mol.
Biol. 334, 103–118.
[27] Enshell-Seijffers, D., Denisov, D., Groisman, B., Smelyanski, L., Meyuhas, R.,
Gross, G., Denisova, G. and Gershoni, J.M. (2003) The mapping and
reconstitution of a conformational discontinuous B-cell epitope of HIV-1. J.
Mol. Biol. 334, 87–101.
[28] Enshell-Seijffers, D., Smelyanski, L., Vardinon, N., Yust, I. and Gershoni, J.M.
(2001) Dissection of the humoral immune response toward an
immunodominant epitope of HIV: a model for the analysis of antibody
diversity in HIV+ individuals. FASEB J. 15, 2112–2120.[29] Fack, F., Hugle-Dorr, B., Song, D., Queitsch, I., Petersen, G. and Bautz, E.K.
(1997) Epitope mapping by phage display: random versus gene-fragment
libraries. J. Immunol. Methods 206, 43–52.
[30] Folgori, A., Taﬁ, R., Meola, A., Felici, F., Galfre, G., Cortese, R., Monaci, P. and
Nicosia, A. (1994) A general strategy to identify mimotopes of pathological
antigens using only random peptide libraries and human sera. EMBO J. 13,
2236–2243.
[31] Foord, A.J., Muller, J.D., Yu, M., Wang, L.F. and Heine, H.G. (2007) Production
and application of recombinant antibodies to foot-and-mouth disease virus
non-structural protein 3ABC. J. Immunol. Methods 321, 142–151.
[32] Freund, N.T., Enshell-Seijffers, D. and Gershoni, J.M. (2009) Phage display
selection, analysis, and prediction of B cell epitopes. Curr. Protoc. Immunol..
Chapter 9:Unit 9 8.
[33] Geysen, H.M., Meloen, R.H. and Barteling, S.J. (1984) Use of peptide synthesis
to probe viral antigens for epitopes to a resolution of a single amino acid.
Proc. Natl. Acad. Sci. USA 81, 3998–4002.
[34] Glanville, J., Zhai, W., Berka, J., Telman, D., Huerta, G., Mehta, G.R., Ni, I., Mei,
L., Sundar, P.D., Day, G.M., Cox, D., Rajpal, A. and Pons, J. (2009) Precise
determination of the diversity of a combinatorial antibody library gives
insight into the human immunoglobulin repertoire. Proc. Natl. Acad. Sci. USA
106, 20216–20221.
[35] Glenney Jr., J.R., Zokas, L. and Kamps, M.P. (1988) Monoclonal antibodies to
phosphotyrosine. J. Immunol. Methods 109, 277–285.
[36] Goedert, M., Jakes, R. and Vanmechelen, E. (1995) Monoclonal antibody AT8
recognises tau protein phosphorylated at both serine 202 and threonine 205.
Neurosci. Lett. 189, 167–169.
[37] Gould, L.H., Sui, J., Foellmer, H., Oliphant, T., Wang, T., Ledizet, M., Murakami,
A., Noonan, K., Lambeth, C., Kar, K., Anderson, J.F., de Silva, A.M., Diamond,
M.S., Koski, R.A., Marasco, W.A. and Fikrig, E. (2005) Protective and
therapeutic capacity of human single-chain Fv-Fc fusion proteins against
West Nile virus. J. Virol. 79, 14606–14613.
[38] Guan, Y., Sajadi, M.M., Kamin-Lewis, R., Fouts, T.R., Dimitrov, A., Zhang, Z.,
Redﬁeld, R.R., DeVico, A.L., Gallo, R.C. and Lewis, G.K. (2009) Discordant
memory B cell and circulating anti-Env antibody responses in HIV-1
infection. Proc. Natl. Acad. Sci. USA 106, 3952–3957.
[39] Halperin, I., Wolfson, H. and Nussinov, R. (2003) SiteLight: binding-site
prediction using phage display libraries. Protein Sci. 12, 1344–1359.
[40] Hammond, P.W. (2010) Accessing the human repertoire for broadly
neutralizing HIV antibodies. MAbs 2, 157–164.
[41] Huang, C.C., Venturi, M., Majeed, S., Moore, M.J., Phogat, S., Zhang, M.Y.,
Dimitrov, D.S., Hendrickson, W.A., Robinson, J., Sodroski, J., Wyatt, R., Choe,
H., Farzan, M. and Kwong, P.D. (2004) Structural basis of tyrosine sulfation
and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-
binding site on gp120. Proc. Natl. Acad. Sci. USA 101, 2706–2711.
[42] Humbert, M., Antoni, S., Brill, B., Landersz, M., Rodes, B., Soriano, V.,
Wintergerst, U., Knechten, H., Staszewski, S., von Laer, D., Dittmar, M.T. and
Dietrich, U. (2007) Mimotopes selected with antibodies from HIV-1-
neutralizing long-term non-progressor plasma. Eur. J. Immunol. 37, 501–515.
[43a] Huse, W.D., Sastry, L., Iverson, S.A., Kang, A.S., Alting-Mees, M., Burton, D.R.,
Benkovic, S.J. and Lerner, R.A. (1989) Generation of a large combinatorial
library of the immunoglobulin repertoire in phage lambda. Science 246,
1275–1281.
[43b] Hwang, W.C., Lin, Y., Santelli, E., Sui, J., Jaroszewski, L., Stec, B., Farzan, M.,
Marasco, W.A. and Liddington, R.C. (2006) Structural basis of neutralization
by a human anti-severe acute respiratory syndrome spike protein antibody.
80R. J Biol Chem 281, 34610–34616.
[44] Jolivet-Reynaud, C., Perron, H., Ferrante, P., Becquart, L., Dalbon, P. and
Mandrand, B. (1999) Speciﬁcities of multiple sclerosis cerebrospinal ﬂuid and
serum antibodies against mimotopes. Clin. Immunol. 93, 283–293.
[45] Kalnina, Z., Silina, K., Meistere, I., Zayakin, P., Rivosh, A., Abols, A., Leja, M.,
Minenkova, O., Schadendorf, D. and Line, A. (2008) Evaluation of T7 and
lambda phage display systems for survey of autoantibody proﬁles in cancer
patients. J. Immunol. Methods 334, 37–50.
[46] Kashyap, A.K., Steel, J., Oner, A.F., Dillon, M.A., Swale, R.E., Wall, K.M., Perry,
K.J., Faynboym, A., Ilhan, M., Horowitz, M., Horowitz, L., Palese, P., Bhatt, R.R.
and Lerner, R.A. (2008) Combinatorial antibody libraries from survivors of the
Turkish H5N1 avian inﬂuenza outbreak reveal virus neutralization strategies.
Proc. Natl. Acad. Sci. USA 105, 5986–5991.
[47] Khurana, S., Needham, J., Mathieson, B., Rodriguez-Chavez, I.R., Catanzaro,
A.T., Bailer, R.T., Kim, J., Polonis, V., Cooper, D.A., Guerin, J., Peterson, M.L.,
Gurwith, M., Nguyen, N., Graham, B.S. and Golding, H. (2006) Human
immunodeﬁciency virus (HIV) vaccine trials: a novel assay for differential
diagnosis of HIV infections in the face of vaccine-generated antibodies. J.
Virol. 80, 2092–2099.
[48] Khurana, S., Needham, J., Park, S., Mathieson, B., Busch, M.P., Nemo, G.,
Nyambi, P., Zolla-Pazner, S., Laal, S., Mulenga, J., Chomba, E., Hunter, E., Allen,
S., McIntyre, J., Hewlett, I., Lee, S., Tang, S., Cowan, E., Beyrer, C., Altfeld, M.,
Yu, X.G., Tounkara, A., Koita, O., Kamali, A., Nguyen, N., Graham, B.S., Todd, D.,
Mugenyi, P., Anzala, O., Sanders, E., Ketter, N., Fast, P. and Golding, H. (2006)
Novel approach for differential diagnosis of HIV infections in the face of
vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.
J. Acquir. Immune Deﬁc. Syndr. 43, 304–312.
[49] Kim, S.H. and Park, S.Y. (2002) Selection and characterization of human
antibodies against hepatitis B virus surface antigen (HBsAg) by phage-
display. Hybrid Hybridomics 21, 385–392.
324 Y. Weiss-Ottolenghi, J.M. Gershoni / FEBS Letters 588 (2014) 318–325[50] Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting
antibody of predeﬁned speciﬁcity. Nature 256, 495–497.
[51] Lanzavecchia, A., Bernasconi, N., Traggiai, E., Ruprecht, C.R., Corti, D. and
Sallusto, F. (2006) Understanding and making use of human memory B cells.
Immunol. Rev. 211, 303–309.
[52] Lanzavecchia, A., Corti, D. and Sallusto, F. (2007) Human monoclonal
antibodies by immortalization of memory B cells. Curr. Opin. Biotechnol.
18, 523–528.
[53] Lanzavecchia, A. and Sallusto, F. (2009) Human B cell memory. Curr. Opin.
Immunol. 21, 298–304.
[54] Larman, H.B., Zhao, Z., Laserson, U., Li, M.Z., Ciccia, A., Gakidis, M.A., Church,
G.M., Kesari, S., Leproust, E.M., Solimini, N.L. and Elledge, S.J. (2011)
Autoantigen discovery with a synthetic human peptidome. Nat. Biotechnol.
29, 535–541.
[55] Liu, I.J., Hsueh, P.R., Lin, C.T., Chiu, C.Y., Kao, C.L., Liao, M.Y. and Wu, H.C.
(2004) Disease-speciﬁc B Cell epitopes for serum antibodies from patients
with severe acute respiratory syndrome (SARS) and serologic detection of
SARS antibodies by epitope-based peptide antigens. J. Infect. Dis. 190, 797–
809.
[56] Lowe, D. and Jermutus, L. (2004) Combinatorial protein biochemistry for
therapeutics and proteomics. Curr. Pharm. Biotechnol. 5, 17–27.
[57] Maecker, H.T., Lindstrom, T.M., Robinson, W.H., Utz, P.J., Hale, M., Boyd, S.D.,
Shen-Orr, S.S. and Fathman, C.G. (2012) New tools for classiﬁcation and
monitoring of autoimmune diseases. Nat. Rev. Rheumatol. 8, 317–328.
[58] Marasco, W.A. and Sui, J. (2007) The growth and potential of human antiviral
monoclonal antibody therapeutics. Nat. Biotechnol. 25, 1421–1434.
[59] Mayrose, I., Penn, O., Erez, E., Rubinstein, N.D., Shlomi, T., Freund, N.T., Bublil,
E.M., Ruppin, E., Sharan, R., Gershoni, J.M., Martz, E. and Pupko, T. (2007)
Pepitope: epitope mapping from afﬁnity-selected peptides. Bioinformatics
23, 3244–3246.
[60] McCafferty, J., Grifﬁths, A.D., Winter, G. and Chiswell, D.J. (1990) Phage
antibodies: ﬁlamentous phage displaying antibody variable domains. Nature
348, 552–554.
[61] Moody, M.A., Yates, N.L., Amos, J.D., Drinker, M.S., Eudailey, J.A., Gurley, T.C.,
Marshall, D.J., Whitesides, J.F., Chen, X., Foulger, A., Yu, J.S., Zhang, R.,
Meyerhoff, R.R., Parks, R., Scull, J.C., Wang, L., Vandergrift, N.A., Pickeral, J.,
Pollara, J., Kelsoe, G., Alam, S.M., Ferrari, G., Monteﬁori, D.C., Voss, G., Liao,
H.X., Tomaras, G.D. and Haynes, B.F. (2012) HIV-1 gp120 vaccine induces
afﬁnity maturation in both new and persistent antibody clonal lineages. J.
Virol. 86, 7496–7507.
[62] Moody, M.A., Zhang, R., Walter, E.B., Woods, C.W., Ginsburg, G.S., McClain,
M.T., Denny, T.N., Chen, X., Munshaw, S., Marshall, D.J., Whitesides, J.F.,
Drinker, M.S., Amos, J.D., Gurley, T.C., Eudailey, J.A., Foulger, A., DeRosa, K.R.,
Parks, R., Meyerhoff, R.R., Yu, J.S., Kozink, D.M., Barefoot, B.E., Ramsburg, E.A.,
Khurana, S., Golding, H., Vandergrift, N.A., Alam, S.M., Tomaras, G.D., Kepler,
T.B., Kelsoe, G., Liao, H.X. and Haynes, B.F. (2011) H3N2 inﬂuenza infection
elicits more cross-reactive and less clonally expanded anti-hemagglutinin
antibodies than inﬂuenza vaccination. PLoS One 6, e25797.
[63] Moreau, V., Granier, C., Villard, S., Laune, D. and Molina, F. (2006)
Discontinuous epitope prediction based on mimotope analysis.
Bioinformatics 22, 1088–1095.
[64] Moulard, M., Phogat, S.K., Shu, Y., Labrijn, A.F., Xiao, X., Binley, J.M., Zhang,
M.Y., Sidorov, I.A., Broder, C.C., Robinson, J., Parren, P.W., Burton, D.R. and
Dimitrov, D.S. (2002) Broadly cross-reactive HIV-1-neutralizing human
monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc.
Natl. Acad. Sci. USA 99, 6913–6918.
[65] Paige, C.J. and Wu, G.E. (1989) The B cell repertoire. FASEB J. 3, 1818–1824.
[66] Petersen, G., Song, D., Hugle-Dorr, B., Oldenburg, I. and Bautz, E.K. (1995)
Mapping of linear epitopes recognized by monoclonal antibodies with gene-
fragment phage display libraries. Mol. Gen. Genet. 249, 425–431.
[67] Pinna, D., Corti, D., Jarrossay, D., Sallusto, F. and Lanzavecchia, A. (2009)
Clonal dissection of the human memory B-cell repertoire following infection
and vaccination. Eur. J. Immunol. 39, 1260–1270.
[68] Poulsen, T.R., Jensen, A., Haurum, J.S. and Andersen, P.S. (2011) Limits for
antibody afﬁnity maturation and repertoire diversiﬁcation in
hypervaccinated humans. J. Immunol. 187, 4229–4235.
[69] Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X. and
Dimitrov, D.S. (2006) Structure of severe acute respiratory syndrome
coronavirus receptor-binding domain complexed with neutralizing
antibody. J. Biol. Chem. 281, 15829–15836.
[70] Reddy, S.T., Ge, X., Miklos, A.E., Hughes, R.A., Kang, S.H., Hoi, K.H.,
Chrysostomou, C., Hunicke-Smith, S.P., Iverson, B.L., Tucker, P.W., Ellington,
A.D. and Georgiou, G. (2010) Monoclonal antibodies isolated without
screening by analyzing the variable-gene repertoire of plasma cells. Nat.
Biotechnol. 28, 965–969.
[71] Rintamaki, E., Salonen, M., Suoranta, U.M., Carlberg, I., Andersson, B. and Aro,
E.M. (1997) Phosphorylation of light-harvesting complex II and photosystem
II core proteins shows different irradiance-dependent regulation in vivo.
Application of phosphothreonine antibodies to analysis of thylakoid
phosphoproteins. J. Biol. Chem. 272, 30476–30482.
[72] Robinson, W.H. (2006) Antigen arrays for antibody proﬁling. Curr. Opin.
Chem. Biol. 10, 67–72.
[73] Rubinstein, N.D., Mayrose, I., Halperin, D., Yekutieli, D., Gershoni, J.M. and
Pupko, T. (2008) Computational characterization of B-cell epitopes. Mol.
Immunol. 45, 3477–3489.[74] Ryvkin, A., Ashkenazy, H., Smelyanski, L., Kaplan, G., Penn, O., Weiss-
Ottolenghi, Y., Privman, E., Ngam, P.B., Woodward, J.E., May, G.D., Bell, C.,
Pupko, T. and Gershoni, J.M. (2012) Deep Panning: steps towards probing the
IgOme. PLoS One 7, e41469.
[75] Saggy, I., Wine, Y., Shefet-Carasso, L., Nahary, L., Georgiou, G. and Benhar, I.
(2012) Antibody isolation from immunized animals: comparison of phage
display and antibody discovery via V gene repertoire mining. Protein Eng.
Des. Sel. 25, 539–549.
[76] Scala, G., Chen, X., Liu, W., Telles, J.N., Cohen, O.J., Vaccarezza, M., Igarashi, T.
and Fauci, A.S. (1999) Selection of HIV-speciﬁc immunogenic epitopes by
screening random peptide libraries with HIV-1-positive sera. J. Immunol.
162, 6155–6161.
[77] Scheid, J.F., Mouquet, H., Feldhahn, N., Seaman, M.S., Velinzon, K., Pietzsch, J.,
Ott, R.G., Anthony, R.M., Zebroski, H., Hurley, A., Phogat, A., Chakrabarti, B., Li,
Y., Connors, M., Pereyra, F., Walker, B.D., Wardemann, H., Ho, D., Wyatt, R.T.,
Mascola, J.R., Ravetch, J.V. and Nussenzweig, M.C. (2009) Broad diversity of
neutralizing antibodies isolated from memory B cells in HIV-infected
individuals. Nature 458, 636–640.
[78] Scheid, J.F., Mouquet, H., Feldhahn, N., Walker, B.D., Pereyra, F., Cutrell, E.,
Seaman, M.S., Mascola, J.R., Wyatt, R.T., Wardemann, H. and Nussenzweig,
M.C. (2009) A method for identiﬁcation of HIV gp140 binding memory B cells
in human blood. J. Immunol. Methods 343, 65–67.
[79] Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y.,
Pietzsch, J., Fenyo, D., Abadir, A., Velinzon, K., Hurley, A., Myung, S., Boulad, F.,
Poignard, P., Burton, D.R., Pereyra, F., Ho, D.D., Walker, B.D., Seaman, M.S.,
Bjorkman, P.J., Chait, B.T. and Nussenzweig, M.C. (2011) Sequence and
structural convergence of broad and potent HIV antibodies that mimic CD4
binding. Science 333, 1633–1637.
[80] Schreiber, A., Humbert, M., Benz, A. and Dietrich, U. (2005) 3D-Epitope-
Explorer (3DEX): localization of conformational epitopes within three-
dimensional structures of proteins. J. Comput. Chem. 26, 879–887.
[81] Scott, J.K. and Smith, G.P. (1990) Searching for peptide ligands with an
epitope library. Science 249, 386–390.
[82] Shin, J.S., Yu, J., Lin, J., Zhong, L., Bren, K.L. and Nahm, M.H. (2002) Peptide
mimotopes of pneumococcal capsular polysaccharide of 6B serotype: a
peptide mimotope can bind to two unrelated antibodies. J. Immunol. 168,
6273–6278.
[83] Siman-Tov, D.D., Navon-Perry, L., Haigwood, N.L. and Gershoni, J.M. (2006)
Differentiation of a passive vaccine and the humoral immune response
toward infection: analysis of phage displayed peptides. Vaccine 24, 607–612.
[84] Smith, G.P. (1985) Filamentous fusion phage: novel expression vectors that
display cloned antigens on the virion surface. Science 228, 1315–1317.
[85] Somers, V., Govarts, C., Somers, K., Hupperts, R., Medaer, R. and Stinissen, P.
(2008) Autoantibody proﬁling in multiple sclerosis reveals novel antigenic
candidates. J. Immunol. 180, 3957–3963.
[86] Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L.J., Wong, S.K., Moore, M.J.,
Tallarico, A.S., Olurinde, M., Choe, H., Anderson, L.J., Bellini, W.J., Farzan, M.
and Marasco, W.A. (2004) Potent neutralization of severe acute respiratory
syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks
receptor association. Proc. Natl. Acad. Sci. USA 101, 2536–2541.
[87] Taﬁ, R., Bandi, R., Prezzi, C., Mondelli, M.U., Cortese, R., Monaci, P. and Nicosia,
A. (1997) Identiﬁcation of HCV core mimotopes: improved methods for the
selection and use of disease-related phage-displayed peptides. Biol. Chem.
378, 495–502.
[88] Tang, S.S., Tan, W.S., Devi, S., Wang, L.F., Pang, T. and Thong, K.L. (2003)
Mimotopes of the Vi antigen of Salmonella enterica serovar typhi identiﬁed
from phage display peptide library. Clin. Diagn. Lab. Immunol. 10, 1078–
1084.
[89] Tarnovitski, N., Matthews, L.J., Sui, J., Gershoni, J.M. and Marasco, W.A. (2006)
Mapping a neutralizing epitope on the SARS coronavirus spike protein:
computational prediction based on afﬁnity-selected peptides. J. Mol. Biol.
359, 190–201.
[90] Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L.L., Alard, P.,
Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., Cinatl, J., ter
Meulen, J., Lasters, I., Carsetti, R., Peiris, M., de Kruif, J. and Goudsmit, J. (2008)
Heterosubtypic neutralizing monoclonal antibodies cross-protective against
H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3,
e3942.
[91] Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo,
M.R., Murphy, B.R., Rappuoli, R. and Lanzavecchia, A. (2004) An efﬁcient
method to make human monoclonal antibodies from memory B cells: potent
neutralization of SARS coronavirus. Nat. Med. 10, 871–875.
[92] van Zonneveld, A.J., van den Berg, B.M., van Meijer, M. and Pannekoek, H.
(1995) Identiﬁcation of functional interaction sites on proteins using
bacteriophage-displayed random epitope libraries. Gene 167, 49–52.
[93] Voak, D. (1990) Monoclonal antibodies as blood grouping reagents. Baillieres
Clin. Haematol. 3, 219–242.
[94] Walker, L.M., Phogat, S.K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J.L.,
Wrin, T., Simek, M.D., Fling, S., Mitcham, J.L., Lehrman, J.K., Priddy, F.H., Olsen,
O.A., Frey, S.M., Hammond, P.W., Kaminsky, S., Zamb, T., Moyle, M., Koff, W.C.,
Poignard, P. and Burton, D.R. (2009) Broad and potent neutralizing antibodies
from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–
289.
[95] Wang, M., Li, X., Chen, J., Zhou, Y., Cao, H., Wu, X. and Jiang, H. (2011)
Screening and evaluating the mimic peptides as a useful serum biomarker of
Y. Weiss-Ottolenghi, J.M. Gershoni / FEBS Letters 588 (2014) 318–325 325ankylosing spondylitis using a phage display technique. Rheumatol. Int. 31,
1009–1016.
[96] Weinstein, J.A., Jiang, N., White 3rd, R.A., Fisher, D.S. and Quake, S.R. (2009)
High-throughput sequencing of the zebraﬁsh antibody repertoire. Science
324, 807–810.
[97] Wilson, P.C. and Andrews, S.F. (2012) Tools to therapeutically harness the
human antibody response. Nat. Rev. Immunol. 12, 709–719.
[98] Wine, Y., Boutz, D.R., Lavinder, J.J., Miklos, A.E., Hughes, R.A., Hoi, K.H., Jung,
S.T., Horton, A.P., Murrin, E.M., Ellington, A.D., Marcotte, E.M. and Georgiou,
G. (2013) Molecular deconvolution of the monoclonal antibodies that
comprise the polyclonal serum response. Proc. Natl. Acad. Sci. USA 110,
2993–2998.
[99] Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T.,
Schmidt, S.D., Wu, L., Xu, L., Longo, N.S., McKee, K., O’Dell, S., Louder, M.K.,
Wycuff, D.L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P.D.,
Roederer, M., Wyatt, R.T., Nabel, G.J. and Mascola, J.R. (2010) Rational design of
envelope identiﬁes broadly neutralizing human monoclonal antibodies to
HIV-1. Science 329, 856–861.
[100] Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I., Wang, C., Chen, X., Longo, N.S.,
Louder, M., McKee, K., O’Dell, S., Perfetto, S., Schmidt, S.D., Shi, W., Wu, L.,
Yang, Y., Yang, Z.Y., Yang, Z., Zhang, Z., Bonsignori, M., Crump, J.A., Kapiga,
S.H., Sam, N.E., Haynes, B.F., Simek, M., Burton, D.R., Koff, W.C., Doria-Rose,
N.A., Connors, M., Mullikin, J.C., Nabel, G.J., Roederer, M., Shapiro, L., Kwong,
P.D. and Mascola, J.R. (2011) Focused evolution of HIV-1 neutralizing
antibodies revealed by structures and deep sequencing. Science 333, 1593–
1602.[101] Zhang, M.Y., Choudhry, V., Sidorov, I.A., Tenev, V., Vu, B.K., Choudhary, A., Lu,
H., Stiegler, G.M., Katinger, H.W., Jiang, S., Broder, C.C. and Dimitrov, D.S.
(2006) Selection of a novel gp41-speciﬁc HIV-1 neutralizing human antibody
by competitive antigen panning. J. Immunol. Methods 317, 21–30.
[102] Zhang, M.Y., Yuan, T., Li, J., Rosa Borges, A., Watkins, J.D., Guenaga, J., Yang, Z.,
Wang, Y., Wilson, R., Li, Y., Polonis, V.R., Pincus, S.H., Ruprecht, R.M. and
Dimitrov, D.S. (2012) Identiﬁcation and characterization of a broadly cross-
reactive HIV-1 human monoclonal antibody that binds to both gp120 and
gp41. PLoS One 7, e44241.
[103] Zhang, Z., Xu, L. and Wang, Z. (2011) Screening serum biomarkers for early
primary hepatocellular carcinoma using a phage display technique. J. Clin.
Lab. Anal. 25, 402–408.
[104] Zhong, L., Coe, S.P., Stromberg, A.J., Khattar, N.H., Jett, J.R. and Hirschowitz,
E.A. (2006) Proﬁling tumor-associated antibodies for early detection of non-
small cell lung cancer. J. Thorac. Oncol. 1, 513–519.
[105] Zhou, T., Xu, L., Dey, B., Hessell, A.J., Van Ryk, D., Xiang, S.H., Yang, X., Zhang,
M.Y., Zwick, M.B., Arthos, J., Burton, D.R., Dimitrov, D.S., Sodroski, J., Wyatt, R.,
Nabel, G.J. and Kwong, P.D. (2007) Structural deﬁnition of a conserved
neutralization epitope on HIV-1 gp120. Nature 445, 732–737.
[106] Zhu, J., Ofek, G., Yang, Y., Zhang, B., Louder, M.K., Lu, G., McKee, K., Pancera,
M., Skinner, J., Zhang, Z., Parks, R., Eudailey, J., Lloyd, K.E., Blinn, J., Alam, S.M.,
Haynes, B.F., Simek, M., Burton, D.R., Koff, W.C., Mullikin, J.C., Mascola, J.R.,
Shapiro, L. and Kwong, P.D. (2013) Mining the antibodyome for HIV-1-
neutralizing antibodies with next-generation sequencing and phylogenetic
pairing of heavy/light chains. Proc. Natl. Acad. Sci. USA 110, 6470–
6475.
